Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Post Herpetic Neuralgia: later-stage trial registry

1 of 5 indexed Post Herpetic Neuralgia trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Post Herpetic Neuralgia: 5 US clinical trials tracked, 1 recruiting.

Post Herpetic Neuralgia is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of California, San Francisco, running 2 of these trials.

Enrollment posture brief

Registry condition post-herpetic-neuralgia

OPEN 1 | RECR 20% | LATE 2 | EARLY 1 | RANK #3391 | SPON 2

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Post Herpetic Neuralgia (thi…20%
Open-enrollment share among volume-matched conditions near Post Herpetic Neuralgia

Post Herpetic Neuralgia lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Post Herpetic Neuralgia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Post Herpetic Neuralgia is recruiting below its size-band peers.

    1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Post Herpetic Neuralgia research.

    University of California, San Francisco accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Post Herpetic Neuralgia trials plan to enrol fewer than 100 people.

    Median target enrolment is 62 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.

  4. Post Herpetic Neuralgia research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21Phase 42

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 4 2

Named interventions

Most-linked intervention names on Post Herpetic Neuralgia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Gabapentin 300 mg capsules 1800 mg/day + placebo patch Drug
1 trials
Gabapentin + Lidoderm® Drug
1 trials
Gabapentin + Placebo Drug
1 trials
Placebo capsules + Lidoderm® Drug
1 trials
Placebo Capsules + Placebo Patch Drug
1 trials
TV-45070 Drug
1 trials
pregabalin Drug
1 trials
Low Frequency rTMS Device
1 trials

US sites by state

Facility locations filed on Post Herpetic Neuralgia trials. A trial with sites in several states counts in each.

California 4 trials
Florida 3 trials
Arizona 3 trials
Pennsylvania 2 trials
Arkansas 2 trials
Alabama 2 trials
Wisconsin 1 trials
Washington 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Post Herpetic Neuralgia page

5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Post Herpetic Neuralgia condition card totals 5 registered trials; most-linked intervention Gabapentin 300 mg capsules 1800 mg/day + placebo patch; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.